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Inhibition of LtxA Toxicity by Blocking Cholesterol Binding with Peptides
Abstract
The leukotoxin (LtxA) produced by Aggregatibacter actinomycetemcomitans kills host immune cells,
allowing the bacterium to establish an ecological niche in the upper aerodigestive tract of its human host.
The interaction of LtxA with human immune cells is both complex and multifaceted, involving membrane
lipids as well as cell-surface proteins. In the initial encounter with the host cell, LtxA associates with
lymphocyte function-associated antigen-1, a cell surface adhesion glycoprotein. However, we have also
demonstrated that the toxin associates strongly with the plasma membrane lipids, specifically
cholesterol. This association with cholesterol is regulated by a cholesterol recognition amino acid
consensus (CRAC) motif, with a sequence of 334LEEYSKR340, in the N-terminal region of the toxin. Here,
we have demonstrated that removal of cholesterol from the plasma membrane or mutation of the LtxA
CRAC motif inhibits the activity of the toxin in THP-1 cells. To inhibit LtxA activity, we designed a short
peptide corresponding to the CRAC336 motif of LtxA (CRAC336WT). This peptide binds to cholesterol and
thereby inhibits the toxicity of LtxA in THP-1 cells. Previously, we showed that this peptide inhibits LtxA
toxicity against Jn.9 (Jurkat) cells, indicating that peptides derived from the cholesterol-binding site of
LtxA may have a potential clinical applicability in controllinginfections of repeats-in-toxin-producing
organisms. © 2016 John Wiley & Sons A/S.
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SUMMARY
The leukotoxin (LtxA) produced by Aggregatibacter actinomycetemcomitans kills host immune
cells, allowing the bacterium to establish an ecological niche in the upper aerodigestive tract of
its human host. The interaction of LtxA with
human immune cells is both complex and multifaceted, involving membrane lipids as well as
cell-surface proteins. In the initial encounter with
the host cell, LtxA associates with lymphocyte
function-associated antigen-1, a cell surface adhesion glycoprotein. However, we have also demonstrated that the toxin associates strongly with the
plasma membrane lipids, speciﬁcally cholesterol.
This association with cholesterol is regulated by
a cholesterol recognition amino acid consensus
(CRAC) motif, with a sequence of 334LEEYSKR340,
in the N-terminal region of the toxin. Here, we
have demonstrated that removal of cholesterol
from the plasma membrane or mutation of the
LtxA CRAC motif inhibits the activity of the toxin
in THP-1 cells. To inhibit LtxA activity, we
designed a short peptide corresponding to the
CRAC336 motif of LtxA (CRAC336WT). This peptide
binds to cholesterol and thereby inhibits the toxicity of LtxA in THP-1 cells. Previously, we showed
that this peptide inhibits LtxA toxicity against Jn.9
(Jurkat) cells, indicating that peptides derived
from the cholesterol-binding site of LtxA may
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have a potential clinical applicability in controlling infections of repeats-in-toxin-producing
organisms.

INTRODUCTION
The pathogenicity of Aggregatibacter actinomycetemcomitans is regulated by a number of virulence factors (Fives-Taylor et al., 1999), including a leukotoxin
(LtxA) that selectively kills human immune cells
(Taichman et al., 1987), allowing the organism to colonize the host. As a member of the repeats-in-toxin
(RTX) family of protein toxins (Welch, 1991), LtxA
shares with this family the common RTX operon organization, which includes ﬁve genes that regulate the
translation and secretion of the toxin. The leukotoxin
operon contains four genes, ltxCABD, where ltxA
encodes the inactive protein (proLtxA), ltxC encodes
an acyltransferase that post-translationally activates
the protoxin (Hardie et al., 1991; Issartel et al., 1991
Hackett et al., 1994; Balashova et al., 2009; Fong
et al., 2011), and ltxB and ltxD, along with a ﬁfth
gene, tdeA (Crosby & Kachlany, 2007), located
572 kb downstream of the ltx operon, produce proteins involved in the secretion of the activated toxin in
a Type I secretion system (Kanonenberg et al.,
2013).
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The mechanism by which LtxA kills cells is congruent with a wide variety of bacterial protein toxins,
whereby target cell recognition initiates a multi-step
process that culminates in cell death (Van Rie et al.,
1989; Parker et al., 1990; London, 1992; Isberg &
Tran Van, 1994; Merritt & Hol, 1995). The RTX toxins
vary in their target cell speciﬁcity, and have historically been classiﬁed as either hemolysins or leukotoxins. The RTX hemolysins, such as Escherichia coli
a-hemolysin (Cavalieri et al., 1984), and Actinobacillus pleuropneumoniae ApxIA (Frey et al., 1991) are
broadly toxic to a wide variety of cell types derived
from many species, whereas the leukotoxins are
much more restrictive in their toxicity. As an RTX
leukotoxin, the A. actinomycetemcomitans LtxA
speciﬁcally kills immune cells from man, the great
apes, and Old World monkeys (Taichman et al.,
1984, 1987) that express the b2 integrin, lymphocyte
function-associated antigen-1 (LFA-1) (Lally et al.,
1997; Kieba et al., 2007). Other RTX toxins, including
Bordetella pertussis adenylate cyclase toxin and the
Mannheimia haemolytica LktA, have been found to
bind to b2 integrins as well (Atapattu & Czuprynski,
2007; Bumba et al., 2010). The exclusive association
of these bacteria with their respective hosts has possibly been driven by parallel evolution of their respective rtxA genes, with the result being the high degree
of target cell speciﬁcity that we now observe.
In addition to these speciﬁc receptor interactions,
LtxA and the RTX cytotoxins are highly membraneactive, with a demonstrated effect on the packing of
the plasma membrane lipids (Martin et al., 2004;
Brown et al., 2012; Barcena-Uribarri et al., 2015) and
a clustering of the toxin and their integrin receptor in
cholesterol-enriched lipid rafts (Fong et al., 2006; Atapattu & Czuprynski, 2007; Bumba et al., 2010).
Examination of the deduced amino acid sequences
of LtxA and several RTX toxins revealed that they
contain cholesterol recognition amino acid consensus
(CRAC) motifs (Brown et al., 2013). We demonstrated that in LtxA, one of these motifs, CRAC336, is
responsible for the cholesterol binding by LtxA that
regulates the lipid raft clustering. In the characterization of the CRAC motif in LtxA, we discovered that a
peptide derived from the CRAC sequence of LtxA is
able to bind to cholesterol and inhibit LtxA binding to
cholesterol. Recently, using molecular dynamics simulations, we have demonstrated that this CRAC peptide interacts strongly with membranes containing
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
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40% cholesterol and that this association results in a
decrease in secondary structure in the peptide, which
is not observed in the absence of cholesterol (Miller
et al., 2014).
In the current work, we have explored the possibility of inhibiting LtxA binding to cholesterol as a means
of inhibiting activity. We found that the interaction
between LtxA and cholesterol is highly speciﬁc,
requiring both an intact CRAC sequence and a speciﬁc sterol structure, and disruption of this interaction in
a number of different ways is sufﬁcient to inhibit LtxA
toxicity. We inhibited the association of LtxA with
cholesterol in the target cell plasma membrane by
removing cholesterol with methyl-b-cyclodextrin
(MbCD), preincubating LtxA with cholesterol-containing liposomes, and blocking plasma membrane
cholesterol with a cholesterol-binding peptide. All
three methods signiﬁcantly reduced the ability of LtxA
to kill THP-1 cells, demonstrating the potential therapeutic use of inhibition of cholesterol-binding by LtxA
to minimize cytotoxicity.
METHODS
Chemicals
1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine
(POPC) was purchased from Avanti Polar Lipids (Alabaster, AL). Cholesterol (Chol), MbCD, and methyl-bcyclodextrin-cholesterol (MbCD-Chol) were purchased
from Sigma-Aldrich (St. Louis, MO), and ergosterol
(Ergo) was purchased from MP Biomedicals (Solon,
OH). Peptides were synthesized and puriﬁed (98%
purity) by Biomatik (Wilmington, DE).
LtxA puriﬁcation
Aggregatibacter actinomycetemcomitans strain JP2
was grown overnight in AAGM broth (Fine et al.,
1999) supplemented with 12.5 lg ml1 vancomycin
and 75 lg ml1 bacitracin. LtxA was puriﬁed as
described previously (Kachlany et al., 2002). The purity of the toxin was conﬁrmed by sodium dodecyl sulfate–polyacrylamide gel electrophoresis and Western
blotting, and the activity was conﬁrmed using a cytotoxicity assay. To inactivate LtxA, the toxin was
heated at 65°C for 30 min.
Production of the CRAC mutant, LtxAY336P,
was accomplished in E. coli using a pSHH plasmid
95
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containing the ltxA-promoter region, ltxC, and the
mutated ltxA genes (Brown et al., 2013). The CRAC
mutant was constructed by substituting proline for tyrosine at amino acid position 336 through site-directed
mutagenesis, performed using a QuikChangeâ site-directed mutagenesis kit (Agilent Technologies, Inc.,
Santa Clara, CA), according to the manufacturer’s
instructions. The primers containing the substitutions
were designed using the OligoPerfectTM Designer, as
shown previously (Brown et al., 2013). The reactions
were performed on an automated thermal cycler with
an initial step of 30 s at 95°C, followed by polymerase chain reaction ampliﬁcation for 16 cycles of
30 s at 95°C, 1 min at 55°C, and 3 min at 68°C. The
polymerase chain reaction products obtained were
transformed into DH5a-T1 cells, and the mutant
clones were selected on Luria–Bertani agar plates
with 50 lg ml1 of ampicillin. The LtxAY336P mutant is
constitutively expressed in the cytosol. To collect this
protein, 200 ml of Luria–Bertani agar supplemented
with ampicillin (50 lg ml1) was inoculated with overnight cultures of the E. coli DH5a-T1 mutant clones
and then grown to an optical density at 600 nm of
approximately 0.4. The cultures were centrifuged and
resuspended in 6 ml of buffer (20 mM Tris–HCl,
250 mM NaCl, 0.2 mM CaCl2, pH 6.8), sonicated (six
times for 45 s, on ice), and centrifuged to remove the
cell debris (12,000 g, 15 min, 4°C).
Liposome preparation
Liposomes composed of POPC and cholesterol were
prepared using the lipid ﬁlm technique. Stock solutions
of POPC and cholesterol (both 25 mg ml1) were prepared in chloroform and then added to a glass vial in
the required amounts. The chloroform was evaporated
under a stream of nitrogen, and the residual chloroform was removed under vacuum to create a thin lipid
ﬁlm on the glass surface. Multilamellar liposomes were
created by hydrating the lipid ﬁlm with phosphate-buffered saline (PBS). Liposomes composed of POPC
and ergosterol were formed using the rapid solvent
exchange technique (Buboltz & Feigenson, 1999).
Stock solutions of POPC and ergosterol were added to
a glass vial, PBS was added directly, and the chloroform was evaporated while the solution was vortexed.
Large unilamellar vesicles were formed from all multilamellar liposome solutions by extrusion (MacDonald
et al., 1991) through a 100-nm polycarbonate What96
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man membrane (GE Healthcare Bio-Sciences, Pittsburgh, PA) 35 times with a LiposoFastâ extruder
(AVESTIN Inc., Ottawa, ON).
Cell culture
THP-1 cells obtained from the American Type Culture
Collection (Manassas, VA) were maintained in RPMI1640 medium containing 10% fetal bovine serum and
0.05 mM 2-mercaptoethanol at 37°C under 5% CO2.
Immunoﬂuorescence
LtxA was labeled with the DyLightâ 647 Amine-Reactive
dye (ThermoScientiﬁc, Waltham, MA), according to the
manufacturer’s instructions with some modiﬁcations.
Speciﬁcally, the toxin was puriﬁed from an excess of the
dye using a 40k MWCO Zeba Spin Desalting column
(ThermoScientiﬁc).
For the LtxA binding studies, 0.5 9 106 THP1 cells ml1 were washed with live cell imaging solution (ThermoScientiﬁc), and the cell nuclei were
stained with 5 lM Hoescht 33342 for 15 min (ThermoScientiﬁc). The cells were then placed for 20 min
in ibiTreat 60 l-dishes (Ibidi, Martinsried, Germany)
coated with poly-L-lysine (Sigma-Aldrich). The
attached cells were covered with 1 ml live cell imaging solution and were examined using a Nikon A1R
laser scanning confocal microscope with a 60 9
water objective (NA 1.2). After the dish was adjusted
on the microscope stage, the initial image was collected, and then 20 ng of LtxA was carefully added to
the cells and images of the same area were collected
for 30 min. The images were processed using Nikon’s
ELEMENTS software 4.1. Approximately 50 cells per
image were analyzed in each experiment to identify
the mean ﬂuorescence intensities by sorting cell-associated areas in three combined Z-planes collected
for each image.
Depletion and replenishment of plasma
membrane cholesterol levels
THP-1 cells, maintained in cell culture media, were
depleted of cholesterol through incubation with 10 mM
MbCD for 15 min at 37°C and 5% CO2. After the
incubation, the cells were washed with cell culture
media to remove any excess MbCD and were used
in the cytotoxicity assay immediately. To replenish
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
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cholesterol, some of the MbCD-treated cells were
subjected to an additional incubation with 1 mM
MbCD-Chol for 1 h at 37°C and 5% CO2. These
cholesterol-replenished cells were then washed and
used immediately. The concentration of cholesterol in
the THP-1 cell membranes before depletion, after
depletion, and after replenishment was measured with
an Amplexâ Red Cholesterol Assay Kit ThermoScientiﬁc (Waltham, MA). Intensity measurements were
performed with an Inﬁnite 200 Pro plate reader (Te€nnedorf, Switzerland) with an excican Group Ltd., Ma
tation wavelength of 555 nm and an emission
wavelength of 580 nm.
Cytotoxicity assays
For the cytotoxicity tests, LtxA-containing samples
were added to THP-1 cells (1 9 106 cells ml1) and
incubated for 3 h. The cell membrane permeability
was determined with a trypan blue assay using an
automated cell counter. Each experiment was performed three times, independently. Untreated cells
were used as a control. (a) To determine the role of
cholesterol in toxicity, cholesterol-depleted and
cholesterol-replenished cells were incubated with
2 lg of LtxA for 3 h. Untreated cells, as well as
cholesterol-depleted and cholesterol-replenished cells
that had not been treated with LtxA, were used as
controls. (b) In the case of the LtxA CRAC mutant,
50 lg of total protein in the E. coli cytosolic fraction
was added to the THP-1 cells and incubated for 3 h.
An E. coli DH5a-T1 cytosolic fraction that did not contain pSHH served as a control. (c) To measure the
protective effect of cholesterol-containing liposomes,
the THP-1 cells were incubated with (i) LtxA, (ii)
LtxA + 100% POPC liposomes, (iii) LtxA + 60%
POPC/40%Chol liposomes, or (iv) LtxA + 60%POPC/
40%Ergo liposomes. The mass of LtxA in each sample was 2 lg, and all liposome concentrations were
9.0 9 107 M. Controls included PBS, 100% POPC
liposomes alone, 60%POPC/40%Chol liposomes
alone, and 60%POPC/40%Ergo liposomes alone. (d)
To measure the protective effect of the CRAC peptide, THP-1 cells were incubated with protein samples
containing (i) LtxA, (ii) LtxA + CRAC336WT or (iii)
LtxA + CRAC336SCR. The mass of LtxA in each sample was 2 lg, and the molar LtxA : peptide ratio was
1 : 100. Controls included PBS, CRAC336WT alone,
and CRAC336SCR alone.
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
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The percentage of cells alive after each treatment
was calculated using the following equation:
%viability ¼

N3
N0

where N0 is the number of cells before treatment,
and N3 is the number of cells after 3 h of treatment.
Peptide binding assay
To measure the binding of the CRAC336WT and
CRAC336SCR peptides to cholesterol, a centrifugation
assay was performed (Sophianopoulos et al., 1978).
The peptides (7.0 9 105 M) were incubated with
100% POPC or 60%POPC/40%Chol liposomes at a
lipid : protein ratio of 100 : 1 for 30 min, then added
to a centrifugal ﬁlter (Amiconâ 30k MWCO; EMD Millipore, Billerica, MA) and centrifuged for 1 h at 6000 g
(Voglino et al., 1998, 1999). The unbound peptide
concentrations were determined by comparing the
intrinsic ﬂuorescence of the eluate at 305 nm to a set
of standards of the same peptide with known concentrations. The ﬂuorescence measurements were
recorded on a Quantamasterâ 400 spectroﬂuorometer
(PTI Horiba, Edison, NJ) using an excitation wavelength of 281 nm. The bound peptide concentrations
were then calculated from the total and free concentrations of peptide.
Statistical analysis
Statistical analysis of the data was performed using
ORIGINPROâ 2015 (OriginLab, Northampton, MA) using
one-way analysis of variance, followed by a Tukey
test. In cases where P > 0.05, we reported no statistically signiﬁcant difference between the two data sets
in question.
RESULTS
LtxA associates with the THP-1 cell surface
We investigated the process of LtxA binding to THP-1
cells, which express active LFA-1 on their surface
(DiFranco et al., 2012) and are highly susceptible to
LtxA (Kachlany et al., 2010). Active and heat-inactivated LtxA was labeled with DyLightâ 647 for confocal imaging. When active DyLightâ 647-LtxA (20 ng)
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was added to THP-1 cells in a time-lapse live confocal imaging experiment, binding of the toxin to the
surface of most of the cells was observed within
5 min (Fig. 1A), as indicated by blue ﬂuorescent
dots accumulating on the cell membrane and presented as mean ﬂuorescence intensity (Fig. 1B). In
contrast, signiﬁcantly less binding was detected when
the same amount of the heat-inactivated DyLightâ
647-LtxA was applied to THP-1 cells, even after a
30-min incubation, suggesting that heat-inactivated
LtxA was inhibited in its ability to interact with the
membrane.
LtxA toxicity is dependent on the presence of
cholesterol
The association of LtxA with the membrane suggests
that the toxin may interact with the cell plasma membrane lipids. Previously, we found that LtxA must bind
to cholesterol on the Jurkat (Jn.9) cell plasma membrane to kill the cells (Brown et al., 2013). To investigate whether LtxA binding to the THP-1 membrane is
likewise regulated by the presence of cholesterol, we
extracted cholesterol from the THP-1 plasma membrane using MbCD and found that the toxicity of LtxA
was signiﬁcantly diminished in the absence of cholesterol (Fig. 2). When the plasma membrane was
replenished with cholesterol, using MbCD followed by
MbCD-Chol, the cells again became susceptible to

A.C. Brown et al.

LtxA, indicating that the interaction of LtxA with
cholesterol on the THP-1 plasma membrane is an
essential element of the toxin’s mechanism of action.
One-way analysis of variance followed by a Tukey
test indicated that the cholesterol-dependence of LtxA
activity is statistically signiﬁcant (Table 2).
Neither treatment with MbCD nor treatment with
MbCD followed by MbCD-Chol was toxic over the
time–course of the experiment (data not shown). The
actual cholesterol concentrations in the cell membrane before and after MbCD treatment were determined using an Amplexâ Red Cholesterol Assay.
Untreated cells had a cholesterol concentration of
112.01  1.87 lM, and after treatment with MbCD,
the cholesterol concentration decreased 67.6% to
36.38  1.34 lM. Replenishment of cholesterol with
MbCD-Chol restored the cholesterol concentration to
near original levels, 104.88  1.34 lM.
LtxA toxicity is regulated by an intact cholesterolbinding site
Previously, we demonstrated that a CRAC motif regulates the binding of LtxA to Jn.9 cells and the resulting toxicity. To conﬁrm that this same CRAC336 motif
regulates cholesterol binding in THP-1 cells as well,
we induced a point mutation (Y336 ? P336) in the ltxA
CRAC336 site using site-directed mutagenesis. The
wild-type and mutant ltxA genes were cloned into

Figure 1 Association of LtxA with THP-1 cells. (A) Confocal images showing the interaction between leukotoxin (LtxA) and THP-1 cells. The
left panel demonstrates the cell before treatment and the right panel demonstrates the same cell 5 min after 20 nM DyLightâ 647-LtxA (light
blue) was added. Cell nuclei were stained with Hoescht 33342 (dark blue). Arrows demonstrate some areas of toxin binding on the plasma
membrane. Representative images are shown. Scale bar = 5 lm. (B) Quantitative ﬂuorescence intensity analysis of confocal microscopy
images indicating association of LtxA and heat-inactivated (HI)-LtxA with THP-1 cells. Each bar represents the summed intensity of 55
regions of interest (ROI). A t-test indicates that there is a signiﬁcant difference in the binding of LtxA and HI-LtxA after 5 min. ***P ≤ 0.001.
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Figure 2 Cytotoxicity of leukotoxin (LtxA) after cholesterol extraction
from THP-1 cells. The toxicity of LtxA was measured in THP-1 cells
as a function of cholesterol composition. THP-1 cells were either
untreated, treated with methyl-b-cyclodextrin (MbCD) for 15 min to
extract cholesterol, or treated with MbCD for 15 min followed by
MbCD-Chol for 1 h to replenish cholesterol. Cells with reduced
cholesterol compositions were signiﬁcantly less susceptible to LtxA
than were those with wild-type cholesterol levels. Replenishment of
cholesterol restored susceptibility to LtxA. The data represent the
averages of three independent experiments, and the error bars represent the standard deviation. A one-way analysis of variance followed
by a Tukey test was used to determine the level of signiﬁcance
between each experiment. ***P ≤ 0.001; N.S., not signiﬁcant.

pSHH and expressed in tandem with the ltxC gene,
under the control of the wild-type promoter. The proteins were constitutively expressed in the cytosol of
E. coli. The bacterial suspensions were sonicated,
and the supernatants were collected and normalized
by the total protein concentration. These normalized
supernatants were then incubated with THP-1 cells,
and the cytotoxicity was measured using a trypan
blue assay. We have previously demonstrated that
LtxACRACY336P is stable and produced at comparable
levels to that of LtxAWT (Brown et al., 2013).
As shown in Fig. 3, after 24 h of exposure to the
E. coli supernatants, cells exposed to LtxAWT had a
very low viability relative to those exposed to a blank
control. Cells exposed to the LtxACRACY336P mutant
remained viable during the time-scale of the experiment, indicating that, as in Jn.9 cells, the CRAC336
site is essential for the toxicity of LtxA in THP-1 cells.
This result suggests that LtxA binds to cholesterol on
the THP-1 plasma membrane during its initial interaction with the cell.
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
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Figure 3 Mutation of the cholesterol-binding site inhibits leukotoxin
(LtxA) cytotoxicity. Point mutations were induced in ltxA by substituting proline for tyrosine at amino acid position 336 using site-directed
mutagenesis. The wild-type ltxA gene and mutant gene were cloned
into pSHH and expressed in tandem with ltxC under the control of
the native LtxA promoter. Overnight cultures of LtxA and LtxAY336P
were constitutively expressed in the Escherichia coli DH5a cytosol.
Escherichia coli cytosolic fractions containing 50 lg of total protein
were incubated with THP-1 cells for 3 h. The THP-1 cells were
highly susceptible to LtxAWT sonicates but not to LtxAY336P. A sonicate from E. coli DH5a containing the pSHH empty vector served
as the negative control. Cell death was measured with a trypan blue
assay. ***P ≤ 0.001; *P ≤ 0.05.

Inhibition of binding to cholesterol inhibits LtxA
toxicity
We investigated the possibility of blocking the binding
of LtxA to cholesterol on the target cell plasma membrane as a means to inhibit the toxin’s activity by
preincubating the toxin with liposomes composed of
POPC and 40% cholesterol. First, we incubated LtxA
with cholesterol-containing liposomes before incubating the mixture with THP-1 cells, with the idea that
the LtxA would bind to cholesterol on the liposome
and therefore be unable to bind to cholesterol on the
cell membrane. Figure 4 demonstrates that this
approach was successful. THP-1 cells were susceptible to free LtxA; however, when the LtxA was preincubated with POPC/Chol liposomes, the cells
remained viable throughout the experiment.
To determine the speciﬁcity of this inhibition, we
repeated the experiment using two types of liposomes that did not contain cholesterol, 100% POPC
liposomes and 60%POPC/40%Ergo liposomes. Ergo
99
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is a sterol found in yeast and other fungal membranes that differs in structure from cholesterol in
both the ring and tail domains. As shown in Fig. 4,
neither type of liposome was able to inhibit LtxA toxicity, demonstrating that the binding of LtxA to cholesterol is speciﬁc to this particular lipid and suggesting
that inhibiting the binding of LtxA to cholesterol could
be an effective approach to alter LtxA activity. The
speciﬁcity of this interaction was statistically signiﬁcant as determined by a one-way analysis of variance
followed by a Tukey test (Table 2).
Cholesterol-binding peptides inhibit LtxA toxicity
We next investigated the possibility of inhibiting LtxA
activity using a cholesterol-binding peptide derived
from the CRAC336 site of LtxA. A cholesterol-binding
peptide (CRAC336WT), consisting of the CRAC336
sequence of LtxA with six ﬂanking residues on either
side, and a scrambled control (CRAC336SCR), in which
the CRAC motif was scrambled, were synthesized for
this purpose. The sequences of the two peptides are
shown in Table 1. An analytical centrifugation assay

Figure 4 Pre-binding to cholesterol inhibits leukotoxin (LtxA) toxicity. LtxA was preincubated with liposomes composed of 60% 1palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) and 40%
cholesterol (Chol) for 15 min before incubation with THP-1 cells.
Preincubation of LtxA with these cholesterol-containing liposomes
completely inhibited the toxicity of LtxA. Preincubation of LtxA with
liposomes without cholesterol, composed of either 100% POPC or
60% POPC/40% ergosterol (Ergo), did not inhibit LtxA toxicity. A
one-way analysis of variance followed by a Tukey test was used to
determine the level of signiﬁcance between each experiment.
***P ≤ 0.001; **P ≤ 0.01; ns, not signiﬁcant.
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was used to demonstrate that the CRAC336WT peptide
binds more effectively to liposomes containing 40%
cholesterol than it does to those without cholesterol
(Fig. 5), indicating that this peptide binds speciﬁcally
to cholesterol in the liposome. Additionally, the
CRAC336WT peptide bound to a greater extent to the
40% cholesterol liposomes than did the CRAC336SCR
peptide, demonstrating that, as in the full-length toxin,
the intact CRAC sequence is essential for this binding. The results of a statistical analysis of these data
are included in Table 2.
Table 1 Cholesterol recognition amino acid consensus (CRAC)
peptide sequences
Name

Sequence

CRAC336WT
CRAC336SCR

FDRARMLEEYSKRFKKFGY
FDRARMYEKLERSFKKFGY

The CRAC motif is underlined and in bold type. Each peptide was
acetylated at the N-terminus and amidated at the C-terminus.

Figure 5 CRAC336WT peptide has a speciﬁc afﬁnity for cholesterol.
A peptide corresponding to the cholesterol-binding motif in leukotoxin (LtxA) (CRAC336WT) was synthesized along with a control peptide in which the cholesterol-binding sequence was scrambled
(CRAC336SCR). The peptides were incubated with liposomes composed of either 100% 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) or 60%POPC/40% cholesterol (Chol) for 30 min.
Unbound peptide was separated from the liposome–peptide complexes using a centrifugal ﬁlter, and the concentration of unbound
peptide was determined by comparing the ﬂuorescence intensity of
the eluate to a set of standards. CRAC336WT bound signiﬁcantly
more to liposomes containing cholesterol than to those without
cholesterol. CRAC336SCR bound with a lower afﬁnity to the POPC/
Chol liposomes than did CRAC336WT. A one-way analysis of variance followed by a Tukey test was used to determine the level of
signiﬁcance between each experiment. **P ≤ 0.001; **P ≤ 0.01.
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This binding experiment was repeated with multiple
liposome concentrations and the half maximal effective liposome concentration (EC50) and the liposome
saturation limit of CRAC336WT binding to POPC/Chol
liposomes were determined using a sigmoidal ﬁt of
the data. The results of this ﬁt predict an EC50 of
3.2 lM and a saturation limit, representing 100% binding of the peptide to the liposomes, of 73.5 mM.
To inhibit LtxA binding to cholesterol and the resulting toxicity, we incubated THP-1 cells with LtxA alone
or in combination with the CRAC336WT peptide or the
CRAC336SCR peptide. As shown in Fig. 6, The
CRAC336WT peptide, but not the CRAC336SCR peptide,
inhibited the activity of LtxA almost completely. A statistical analysis of these results is included in Table 2.
Neither peptide was toxic to the cells at the concentrations used over the time course of the experiment.
To determine the half maximal peptide inhibitory
concentration (IC50) and peptide saturation limit of the
CRAC336WT peptide, the experiment was repeated
with several peptide concentrations, and the data were
ﬁtted to a sigmoidal curve. The results of this ﬁt predict
an IC50 of 6.1 lM and a saturation limit, representing
the peptide concentration resulting in 100% viability of
the cells, of 0.0341 mM for the CRAC336WT peptide.
Previously, we demonstrated that the CRAC336WT
peptide inhibits LtxA toxicity against Jn.9 cells (Brown
et al., 2013). Therefore, this result demonstrates that

Figure 6 CRAC336WT peptide inhibits leukotoxin (LtxA) toxicity. LtxA
and either CRAC336WT or CRAC336SCR were incubated with THP-1
cells for 3 h, and the viability of the cells was measured using a trypan blue assay. The CRAC336WT peptide, which binds to cholesterol, inhibited the toxicity of LtxA, but the CRAC336SCR peptide,
which does not bind to cholesterol, did not inhibit LtxA toxicity. A
one-way analysis of variance followed by a Tukey test was used to
determine the level of signiﬁcance between each experiment.
***P ≤ 0.001; ns, not signiﬁcant.

an LtxA-derived cholesterol-binding peptide can be
used to speciﬁcally alter the binding and subsequent
toxicity of LtxA against several cell types, suggesting
that the approach may have broad applicability in the
treatment of A. actinomycetemcomitans infections.

Table 2 Summary of statistical comparisons of data
Comparison
LtxA
LtxA
MbCD + LtxA
LtxA
LtxA
LtxA
LtxA + POPC
LtxA + POPC
LtxA + POPC/Chol
CRAC336WT + POPC
CRAC336WT + POPC
CRAC336WT + POPC/Chol
LtxA
LtxA
LtxA + CRAC336WT

vs.
vs.
vs.
vs.
vs.
vs.
vs.
vs.
vs.
vs.
vs.
vs.
vs.
vs.
vs.

MbCD + LtxA
MbCD + MbCD-Chol + LtxA
MbCD + MbCD-Chol + LtxA
LtxA + POPC
LtxA + POPC/Chol
LtxA + POPC/Ergo
LtxA + POPC/Chol
LtxA + POPC/Ergo
LtxA + POPC/Ergo
CRAC336WT + POPC/Chol
CRAC336SCR + POPC/Chol
CRAC336SCR + POPC/Chol
LtxA + CRAC336WT
LtxA + CRACSCR336
LtxA + CRACSCR336

P value

Signiﬁcantly different

0.00008
0.07240
0.00003
0.24400
0.00000
0.46400
0.00225
0.98300
0.00103
0.00502
0.00001
0.00000
0.00000
0.24800
0.00001

Yes
No
Yes
No
Yes
No
Yes
No
Yes
Yes
Yes
Yes
Yes
No
Yes

One-way analysis of variance was performed using the Tukey comparisons test within ORIGINPRO 2015.
Chol, cholesterol; CRAC, cholesterol recognition amino acid consensus; Ergo, ergosterol; LtxA, leukotoxin; MbCD, methyl-b-cyclodextrin;
POPC, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine.
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DISCUSSION
More than 90% of cellular cholesterol resides at the
plasma membrane and is essential for cell viability
and proliferation (Yeagle, 1991; van Meer et al.,
2008). Cholesterol is not uniformly dispersed throughout biological membranes; rather, it is sequestered in
membrane microdomains known as lipid rafts (Simons
& Ikonen, 1997), along with sphingolipids and specialized proteins, such as glycosylphosphatidylinositol-anchored proteins, heterotrimeric G protein-coupled
receptors, and Src family kinases (Varma & Mayor,
1998; Simons & Toomre, 2000; Liang et al., 2001;
Chini & Parenti, 2004). Many pathogens and their virulence factors have therefore developed the ability to
recognize and bind to lipid raft cholesterol on the surface of host cells. For example, cholesterol is required
for the uptake of mycobacteria by host cells (Gatﬁeld
& Pieters, 2000) and Leishmania (Pucadyil & Chattopadhyay, 2007) and allows these intracellular pathogens to avoid degradation by inhibiting lysosomal–
phagosomal fusion (Pieters & Gatﬁeld, 2002). In addition, the activity of a number of bacterial toxins
depends on the presence of cholesterol in the target
membrane (Orlandi & Fishman, 1998; Patel et al.,
2002; Schraw et al., 2002; Giddings et al., 2004;
Boesze-Battaglia et al., 2006, 2009; Fong et al., 2006;
Atapattu & Czuprynski, 2007; Bumba et al., 2010; Farrand et al., 2010; Zhao et al., 2012; Brown et al.,
2013; Lai et al., 2013). Inﬂuenza (Sun & Whittaker,
2003), human immunodeﬁciency virus type 1 (Guyader et al., 2002; Liao et al., 2004) and the Ebola virus
(Bavari et al., 2002) also require cholesterol in the
host membrane for binding to and/or exit from the cell.
Previously, we reported that the binding of LtxA to
cholesterol occurs with high afﬁnity (Brown et al.,
2013), suggesting the involvement of a lipid-binding
site within the toxin. Several proteins that interact with
cholesterol have an amino acid sequence in the
juxta-membrane region conforming to the pattern -L/
V-(X1–5)-Y-(X1–5)-R/K-, in which (X1–5) represents
between one and ﬁve residues of any amino acid (Li
& Papadopoulos, 1998). The stringency of this motif
is ﬂexible, and therefore, not all predicted CRAC sites
bind cholesterol or possess an in vivo function. In the
deduced amino acid sequence of LtxA, CRAC336
(334LEEYSKR339) and CRAC503 (502VDYLKK505) were
identiﬁed as potential cholesterol binding sites.
Whereas both sequences are juxtaposed to
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hydrophobic domains in LtxA, only CRAC336 was
found to bind to cholesterol and regulate the toxicity
of LtxA (Brown et al., 2013). CRAC336 is highly conserved among other RTX toxins, suggesting a common cholesterol-binding pathogenesis among the
members of the RTX family, although additional studies to substantiate this are necessary.
In the current study, we used THP-1, a human monocytic leukemia cell line, which expresses LFA-1
(DiFranco et al., 2012), to investigate the role of cholesterol binding by LtxA on its toxicity. Although we and
others have shown that LtxA cytotoxicity requires the
expression of LFA-1 by the host cell (Lally et al., 1997;
Kieba et al., 2007; Kachlany et al., 2010), we have also
shown that LtxA, like other RTX toxins, is strongly membrane-active (Brown et al., 2012, 2013; Walters et al.,
2013) and has a particularly strong afﬁnity (1012 M) for
membranes containing 40% cholesterol (Brown et al.,
2013). This membrane activity is correlated with subtle
conformational changes in the entire protein structure
(Lear et al., 2000; Walters et al., 2013), but a signiﬁcant
decrease in helicity within the cholesterol-binding
domain upon association with cholesterol (Miller et al.,
2014), which allows the protein to move from a watersoluble to a membrane-active state.
This work demonstrates the requirement of cholesterol binding by LtxA in cytotoxicity. Based on this
and our previous results, we can conclude that LtxA
requires both LFA-1 and cholesterol to be present on
the membrane for the toxin to kill the target cells. In
addition, this work suggests that a possible approach
to the inhibition of LtxA activity may be the blocking
of cholesterol binding by the toxin. We are currently
investigating the long-term toxicity of this cholesterolbinding peptide to study its possible clinical use as
an alternative to current, toxic approaches to inhibit
the activity of cholesterol-binding proteins and pathogens. Future work will focus on reﬁning the CRAC
motif in the peptide to enhance cholesterol binding
and improve inhibition of toxin/pathogen binding.
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